

## Australian committees set to advise on translational medicine

Australia's National Health and Medical Research Council (NHMRC), the nation's main funding body for medical research, aims to get more proactive in translating findings from bench to bedside after Health Minister Nicola Roxon approved two new principal committees.

The new Health Care Committee, announced in September, is charged with providing advice to the council and chief executive officer on applying research knowledge to health care in hospitals, surgeries and clinics. The new Prevention and Community Health Committee, meanwhile, will advise on public health and prevention of illness. They will also join the NHMRC's other principal committees—the Research, Health Ethics and Human Genetics committees—in recommending study areas for priority funding.

Describing the dynamics within the NHMRC, Warwick Anderson, its chief executive officer, likens the council to a deliberative body that sets a broad agenda, with the committees driving and implementing that agenda.

“The energy tends to come from the committees,” says Anderson, for whom the establishment of the new committees is a welcome reform. “If we are about research and its translation into better prevention or patient care, you can't just do the research bit.”

In 2009, the NHMRC allocated AU\$860 million (\$790 million) for research, an increase of almost AU\$200 million over the previous year, as the research sector received support from the Australian Government's economic stimulus in response to the financial crisis.

The new 16-member Health Care Committee is chaired by John Horvath, formerly Australia's chief medical officer, and includes Mukesh Haikerwal, a former president of the Australian Medical Association, along with Mark Wenitong, past president and founder of the Australian Indigenous Doctors Association. Likely priorities for this committee are mental health and chronic disease, to be finalized in the new year.

Kerin O'Dea will head the Prevention and Community Health Committee. O'Dea has served as director of the Sansom Institute's

division of health sciences at the University of South Australia and is an expert in nutrition and public health.

The chairs of the five NHMRC committees will form a new Chairs Consultative Group along with Anderson and Michael Good, director of the Queensland Institute of Medical Research. This initiative is designed to ensure that the organization develops what Health Care Committee chairman Horvath calls “whole-of-NHMRC” views and policies.

“The committees should not work as silos,” he says. “The process whereby the NHMRC is going to bring a total view to things is a very important new way through.”

Approval of the new committees comes after the NHMRC has been bolstered by recruitment of more in-house expertise. It is now positioned to take an enhanced role in supporting the national government's health delivery agenda, which has expanded over the last decade as state and territory governments have struggled to maintain service quality.

*Simon Grose, Canberra, Australia*

## In debate over AIDS vaccine success, every detail counts

When a study produces unexpected findings, there can be a cloud of doubt cast over the results. In this sense, the data from the recent AIDS vaccine trial in Thailand created a perfect storm.

The trial aimed to test a combination of two products, each containing the HIV gp120 protein—the ALVAC canarypox-HIV vaccine and AIDSVAX. As early as 2004, some scientists had expressed concerns about the trial because the AIDSVAX and ALVAC formulations did not seem to sufficiently stimulate the immune system when used separately (*Science* **303**, 316; 2004). And, in 2007, disappointing results from the Merck HIV vaccine trial, called STEP, did nothing to allay skepticism about a vaccine approach to thwarting the virus.

On 24 September, the researchers behind the Thai trial announced key findings ahead of a full release of the data one month later at an AIDS vaccine meeting in Paris and in *The New England Journal of Medicine* (*N. Engl. J. Med.*, doi:10.1056/nejmoa0908492; 2009). Much to the surprise of many AIDS researchers, the findings indicated that the vaccine offered some protection against HIV infection.

How much protection, though, became a sticking point. Critics, quoted anonymously in the news media, said that the method used to establish efficacy—the so-called ‘intention-to-treat’ analysis—was not the most relevant analysis. This analysis took into account all 16,395 individuals from the general population who enrolled in the study and were HIV negative at the start of the trial. Of those who received the vaccine, 51 became infected with the virus over the course of the three-year trial, compared with 74 of those in the similarly-sized placebo group—yielding a 31.2 % efficacy rate.

What the study researchers did not release upfront was the ‘per-protocol’ analysis. This considers vaccine efficacy on the basis of the subset of subjects who closely adhered to the vaccine regimen. The involved nature of the study protocol, which consisted of four precisely timed vaccination visits over a six-month period, meant that only 12,542 participants fell into this category—an unusually large drop. As it turned out, the per-protocol analysis suggested a slightly lower efficacy rate, 26.2%. What's more, the calculations suggested that this perceived efficacy

had a higher likelihood of being result of statistical chance than the intention-to-treat analysis (based on *P* values of 0.16 and 0.04, respectively). So when the per-protocol details emerged, a few scientists voiced doubt over the scale of the vaccine trial's success.

Nelson Michael, a researcher with the US Army who helped lead the Thai trial, defends the decision to emphasize the intention-to-treat analysis. “This was considered the most relevant [analysis],” he says. According to Michael, the per-protocol calculation becomes important at a later stage, when one is aiming to license a specific vaccine regimen for marketing purposes.

Others emphasize that the trial functions to show that creating some immunity to HIV is possible and worth exploring further. “It's important for people to understand that the point of the study, and the manner in which it was powered, was to prove a concept,” says Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases at the US National Institutes of Health, which helped to fund the study.

*Roxanne Khamsi, New York*